1.0mg Varenicline b.i.d. + 0.5mg Varenicline b.i.d. + 0.0mg placebo Varenicline b.i.d.
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Tobacco Dependence
Conditions
Tobacco Dependence, Withdrawal Symptoms, Smoking Cessation
Trial Timeline
May 7, 2018 → Apr 16, 2022
NCT ID
NCT03557294About 1.0mg Varenicline b.i.d. + 0.5mg Varenicline b.i.d. + 0.0mg placebo Varenicline b.i.d.
1.0mg Varenicline b.i.d. + 0.5mg Varenicline b.i.d. + 0.0mg placebo Varenicline b.i.d. is a approved stage product being developed by Pfizer for Tobacco Dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT03557294. Target conditions include Tobacco Dependence, Withdrawal Symptoms, Smoking Cessation.
What happened to similar drugs?
6 of 9 similar drugs in Tobacco Dependence were approved
Approved (6) Terminated (3) Active (2)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03557294 | Approved | Completed |
Competing Products
20 competing products in Tobacco Dependence